TTK Healthcare Ltd

TTK Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

TTK Healthcare Ltd

₹ 1,278 -0.37%
30 Jun - close price
ttkhealthcare.com BSE: 507747 NSE: TTKHLTCARE
About

TTK Healthcare Ltd is engaged in the business of Pharmaceuticals, Consumer Products, Medical Devices, Protective Devices and Foods. [1]
It is a part of TT Krishnamachari group; whose flagship company, TTK Prestige Ltd is one of the leading kitchen appliances company in India.[2]

Key Points

Business Segments FY24
1. Consumer Products (~31% revenue, 29% Op. profit): The company markets and distributes products that transcend categories; baby care (Woodward’s Gripe Water), personal care (Eva Deodrants), home care- room & air fresheners (Good Home ), and sexual wellness (Skore).. [1] The Woodward's Gripe Water is one of the oldest FMCG brands worldwide and is a market leader in the Indian colic market. It has been marketed in India since 1928. It has a distribution network of 27 warehouses, 2,600+ distributors, 650+ frontline sales teams, and a reach of ~4 lakh outlets across India. [2]

Website BSE NSE
  • Market Cap ₹ 1,806 Cr.
  • Current Price ₹ 1,278
  • High / Low ₹ 1,923 / 991
  • Stock P/E 25.4
  • Book Value ₹ 754
  • Dividend Yield 0.78 %
  • ROCE 9.26 %
  • ROE 6.89 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 42.0% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%

Cons

  • The company has delivered a poor sales growth of 4.42% over past five years.
  • Earnings include an other income of Rs.85.1 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Diversified Diversified Diversified Diversified

Part of BSE SmallCap BSE Allcap BSE Industrials

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
159 193 170 183 180 202 186 184 181 208 198 205 190
154 189 166 174 165 192 176 179 169 201 190 197 178
Operating Profit 5 4 4 8 15 10 10 5 12 7 8 8 12
OPM % 3% 2% 2% 5% 8% 5% 5% 3% 7% 3% 4% 4% 6%
12 606 13 12 12 15 16 16 16 37 18 18 13
Interest 1 3 1 1 1 1 1 0 1 1 1 1 1
Depreciation 3 3 3 3 3 3 3 3 3 2 2 2 2
Profit before tax 12 604 13 16 23 21 22 18 24 41 23 23 22
Tax % 13% 1% 23% 26% 27% 24% 26% 27% 25% 23% 26% 26% 26%
11 601 10 12 17 16 16 13 18 32 17 17 16
EPS in Rs 7.52 425.23 7.01 8.49 11.99 11.09 11.33 9.12 12.93 22.35 12.17 11.84 11.43
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
416 483 519 528 578 628 646 476 599 725 753 801
396 453 478 489 535 578 617 457 577 694 715 767
Operating Profit 20 30 40 38 43 50 28 19 22 31 37 35
OPM % 5% 6% 8% 7% 7% 8% 4% 4% 4% 4% 5% 4%
6 7 6 6 8 8 9 28 42 643 63 85
Interest 3 4 3 3 5 3 3 2 3 5 3 3
Depreciation 3 6 7 12 15 15 14 13 13 13 13 8
Profit before tax 20 26 36 29 30 39 19 32 48 657 84 108
Tax % 37% 39% 36% 36% 40% 38% 37% -44% 13% 3% 25% 25%
12 16 23 19 18 24 12 46 42 640 63 82
EPS in Rs 15.95 20.81 29.19 24.13 12.86 17.25 8.72 32.87 29.43 452.72 44.47 57.79
Dividend Payout % 25% 22% 17% 21% 39% 29% 34% 18% 34% 2% 22% 17%
Compounded Sales Growth
10 Years: 5%
5 Years: 4%
3 Years: 10%
TTM: 6%
Compounded Profit Growth
10 Years: 16%
5 Years: 42%
3 Years: 22%
TTM: 13%
Stock Price CAGR
10 Years: 4%
5 Years: 24%
3 Years: 18%
1 Year: -13%
Return on Equity
10 Years: 23%
5 Years: 26%
3 Years: 29%
Last Year: 7%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 8 8 8 8 14 14 14 14 14 14 14 14
Reserves 99 110 128 150 219 237 235 281 316 939 987 1,051
32 42 38 23 47 29 30 19 22 27 23 24
102 115 128 104 127 136 152 180 207 189 183 192
Total Liabilities 240 275 303 285 407 416 431 494 559 1,170 1,206 1,281
54 52 106 99 110 98 89 85 80 71 75 81
CWIP 2 46 1 0 1 2 9 0 0 3 1 0
Investments 0 0 10 9 9 13 9 13 15 13 13 11
184 177 185 177 288 304 325 395 463 1,083 1,118 1,189
Total Assets 240 275 303 285 407 416 431 494 559 1,170 1,206 1,281

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
13 39 37 18 25 17 20 96 45 -25 -5 -4
-15 -49 -27 5 -22 10 -13 -77 -30 32 28 20
2 3 -11 -23 -7 -31 -10 -17 -10 -12 -22 -18
Net Cash Flow 0 -7 -0 0 -4 -4 -4 2 5 -6 2 -2

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 34 34 33 24 35 47 43 46 33 46 42 41
Inventory Days 64 62 66 65 80 77 101 123 102 89 105 107
Days Payable 56 50 53 100 130 101 121 170 134 116 110 106
Cash Conversion Cycle 41 46 46 -11 -16 22 23 -2 1 19 36 43
Working Capital Days -12 -14 -22 -9 -1 10 13 -18 -15 17 60 59
ROCE % 17% 20% 23% 18% 15% 15% 8% 6% 8% 10% 9% 9%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
74.56% 74.57% 74.57% 74.57% 74.57% 74.57% 74.57% 74.57% 74.57% 74.57% 74.57% 74.57%
2.34% 2.37% 2.32% 2.38% 2.40% 1.85% 1.85% 1.85% 1.87% 1.90% 1.90% 1.90%
2.51% 2.22% 2.18% 2.99% 3.27% 3.23% 3.13% 1.14% 1.14% 1.14% 1.14% 1.14%
20.59% 20.84% 20.95% 20.07% 19.76% 20.37% 20.46% 22.45% 22.44% 22.39% 22.39% 22.40%
No. of Shareholders 15,22814,61714,99515,81816,10915,67216,65117,22116,93015,76215,78015,899

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Sep 2016
    Transcript
    Notes
    PPT